RecruitingDiabetes Mellitus Type 2, Childhood-Onset
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
Eligible age
8–15 yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.
Sponsor: George Washington University
You may qualify if…
- ✓ Screening will occur to enrich the yield of individuals who are highly predisposed to develop youth-onset T2D and include those with all of the following criteria:
- ✓ Overweight or obesity with BMI ≥85th percentile
- ✓ Age 8-13 year for girls, 9-15 year for boys (inclusion younger for girls as puberty tends to start a year earlier in girls)
- ✓ Tanner Stage 2, 3, or 4
- ✓ Elevated HbA1c 5.5-6.4%
You may not qualify if…
- ✕ An individual who meets any of the following criteria will be excluded from participation:
- ✕ Diabetes based on history, or HbA1c ≥6.5% in the medical record or at screening
- ✕ Unable/unwilling to provide consent/participate fully
- ✕ Conditions predisposing to diabetes or altering the trajectory of puberty
- ✕ Medications affecting glucose dynamics during the screening and enrollment period
- ✕ Prior treatment with insulin
- ✕ Use of glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications in the 6 weeks prior to enrollment
- ✕ Planning treatment with glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications
Where it's recruiting
Alabama
Birmingham
Arizona
Phoenix
California
Los Angeles
Colorado
Aurora
Florida
St. Petersburg
Maryland
Baltimore
Massachusetts
Boston
New Mexico
Shiprock
New York
Brooklyn · Garden City · New York · The Bronx
North Carolina
Charlotte · Winston-Salem
Ohio
Cincinnati · Columbus
Oklahoma
Oklahoma City
Source: ClinicalTrials.gov · NCT06525259 · last updated 2026-05-07